Last reviewed · How we verify
Bosentan administration
Bosentan, marketed by VA Loma Linda Health Care System, is an established drug with a key composition patent expiring in 2028. Its primary strength lies in its well-established market presence and ongoing revenue generation. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Bosentan administration |
|---|---|
| Sponsor | VA Loma Linda Health Care System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (PHASE3)
- Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension (PHASE3)
- Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) (PHASE2)
- Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea (PHASE2)
- A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood (PHASE1)
- A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood (PHASE1)
- Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors (PHASE1)
- COMPERA / COMPERA-KIDS
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bosentan administration CI brief — competitive landscape report
- Bosentan administration updates RSS · CI watch RSS
- VA Loma Linda Health Care System portfolio CI